II
VKTX icon

Inspire Investing’s Viking Therapeutics VKTX Stock Holding History

Inspire Investing’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$661K Buy
16,949
+1,223
+8% +$39.5K 0.03% 903
2026
Q1 		$512K Buy
15,726
+2,348
+18% +$75.5K 0.03% 773
2025
Q4 		$471K Sell
13,378
-3,838
-22% -$136K 0.04% 388
2025
Q3 		$452K Buy
17,216
+2,829
+20% +$84.4K 0.04% 653
2025
Q2 		$381K Buy
14,387
+132
+0.9% +$3.48K 0.04% 718
2025
Q1 		$344K Buy
14,255
+4,170
+41% +$132K 0.04% 492
2024
Q4 		$406K Buy
10,085
+3,566
+55% +$203K 0.05% 379
2024
Q3 		$413K Buy
6,519
+38
+0.6% +$2.23K 0.04% 533
2024
Q2 		$344K Buy
6,481
+2,105
+48% +$138K 0.04% 735
2024
Q1 		$359K Sell
4,376
-17,169
-80% -$764K 0.04% 557
2023
Q4 		$401K Sell
21,545
-6,102
-22% -$79.8K 0.04% 413
2023
Q3 		$306K Buy
27,647
+8,372
+43% +$120K 0.04% 661
2023
Q2 		$312K Buy
+19,275
New +$404K 0.04% 731

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Inspire Investing's VKTX Position: Q2 2026 in Review

Inspire Investing increased its Viking Therapeutics (VKTX) stake by 7.8% in Q2 2026, buying an estimated $39.5K and bringing the position to 16,949 shares worth $661K. The position accounts for 0.03% of the portfolio, ranked #903.

Inspire Investing first reported a position in VKTX in Q2 2023 and has held it in 13 quarters since. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Inspire Investing held 16,949 shares of Viking Therapeutics worth $661K as of Q2 2026.
  • Inspire Investing bought 1,223 Viking Therapeutics shares in Q2 2026, an estimated $39.5K.
  • Viking Therapeutics made up 0.03% of Inspire Investing's portfolio in Q2 2026, its #903 holding.
  • Inspire Investing first reported a position in Viking Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Inspire Investing's 13F filing for Q2 2026, filed 12 Aug 2026.